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37 Abstract 
38 Objectives
39 Subchondral bone and the osteochondral junction are thought to contribute to 
40 osteoarthritis (OA) knee pain. We aimed to identify osteochondral pathologies 
41 specifically associated with symptomatic human knee OA.
42 Methods
43 Two groups of medial tibial plateau (n=31 per group) were matched for macroscopic 
44 chondropathy scores. One group had undergone total knee replacement for OA knee pain 
45 (symptomatic chondropathy). The other had not sought help for knee pain and died from 
46 unrelated illness (asymptomatic chondropathy). OA histopathology, immunoreactivity 
47 for nerve growth factor (NGF) and CD68 (macrophages), tartrate resistant acid 
48 phosphatase (TRAP)-positive subchondral osteoclasts and synovitis were compared 
49 between groups.
50 Results
51 Mankin score, subchondral bone density and subchondral CD68-immunoreactive 
52 macrophage infiltration were similar between the 2 groups. NGF-like immunoreactivity 
53 was in subchondral mononuclear cells and osteoclasts, as well as in chondrocytes. NGF 
54 in osteochondral channels, and osteoclast densities in subchondral bone were higher in 
55 symptomatic than in asymptomatic chondropathy groups (NGF; p<0.01, TRAP; p=0.02), 
56 as also were synovitis scores (p<0.01). Osteochondral pathology was not significantly 
57 associated with synovitis score. The differences in NGF expression and in osteoclast 
58 density remained significant after adjusting for age and synovitis score (NGF; p=0.01, 
59 TRAP; p=0.04). Osteochondral NGF and osteoclast densities, together with synovitis 
60 scores, explained approximately 28% of sample allocation to symptomatic or 
61 asymptomatic groups.
62 Conclusion
63 Subchondral pathology was associated with symptomatic knee OA independently of 
64 chondropathy and synovitis. Increased NGF expression in osteochondral channels, and 
65 osteoclast density appear be key features associated with bone pain in knee OA.
66
67
68
69
70
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71 Introduction 
72 Pain is the major source of disability and reason for hospital visits in patients with knee 
73 osteoarthritis (OA). Structural changes including articular cartilage degradation, synovial 
74 inflammation, osteophytes and subchondral osteosclerosis are characteristic of OA, but 
75 are not always accompanied by severe pain. Recent evidence suggests that subchondral 
76 bone contributes to knee OA pain1-7. Subchondral bone marrow lesions (BMLs) detected 
77 on magnetic resonance imaging (MRI) in knee OA are strongly associated with pain1-4, 7. 
78 Bone attrition, a flattening or depression of the subchondral bone visualised using x-rays 
79 or MRI, is also associated with the presence of pain5, 6. Microarray analysis of BMLs in 
80 OA demonstrated upregulation of genes implicated in neurogenesis, osteochondral 
81 turnover and inflammation that might contribute to OA pain8. In animals, OA caused up-
82 regulation of nociceptive markers (calcitonin gene-related peptide and tropomyosin 
83 receptor kinase A (TrkA)) in subchondral bone afferents9. However, the mechanisms by 
84 which subchondral pathology contribute to OA pain are incompletely understood. 
85 Synovitis has also been associated with OA pain1, 10-13 . Synovial and subchondral 
86 pathology can occur together within the same joint, but it is unknown whether these 
87 represent discrete painful pathologies that could be separate targets for therapeutic 
88 intervention.
89 Nerve growth factor (NGF) plays a key role in the generation of acute and chronic pain, 
90 especially in inflammation14, 15. NGF can bind two receptors: the high affinity TrkA16 and 
91 the low affinity p75 neurotrophin receptor17. NGF blockade can be achieved using 
92 antibodies or TrkA-IgG fusion protein that bind NGF and prevent its interaction with 
93 TrkA and p75 receptors. Recent clinical trials showed that NGF blockade remarkably 
94 reduced OA knee pain18, 19. In human OA, NGF is upregulated in synovium10 and 
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95 subchondral bone20. Increased synovial NGF expression was associated with 
96 symptomatic knee OA10, although the relevance of subchondral NGF expression has not 
97 been clarified. Increased density of tartrate resistant acid phosphatase (TRAP)-positive 
98 osteoclasts in subchondral bone was also associated with OA and knee symptoms21, 22. 
99 Inflammatory CD68-positive macrophages were also detected in subchondral bone 
100 marrow compartments in human OA23. 
101  We hypothesized that structural, cellular and molecular changes in subchondral bone are 
102 associated with symptomatic knee OA. We compared between case groups with similar 
103 macroscopic chondropathy but differing symptom severities. One group had sought help 
104 for knee pain and undergone total knee replacement (TKR) surgery (symptomatic 
105 chondropathy). The other group had not sought help for knee pain but had died from 
106 unrelated illness (asymptomatic chondropathy). We hypothesized that NGF expression 
107 by cells within subchondral bone was associated with symptomatic OA.
108
109 Patients and Methods;
110 Patient samples
111 Cases comprised 31 consecutive symptomatic chondropathy cases who had donated tibial 
112 plateau at TKR for OA and 31 asymptomatic chondropathy cases who had not presented 
113 with knee pain. All symptomatic chondropathy cases undertaking TKR report severe knee 
114 pain. All asymptomatic chondropathy cases had not sought medical attention for knee 
115 pain during the last year. The asymptomatic chondropathy cases are highly likely to have 
116 experienced less pain than the symptomatic chondropathy cases. Asymptomatic 
117 chondropathy cases were selected from 782 consecutive post-mortem (PM) donors by 
118 matching to each symptomatic chondropathy case for macroscopic chondropathy score 
Page 4 of 26
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review
119 and the percentage of joint surface with grade 4 chondropathy lesion [subchondral bone 
120 exposure] (each within ± 5 between matched cases).
121  Informed consent was obtained from TKR cases, or the next of kin of PM cases. 
122 Protocols were approved by Nottingham 1 Research Ethics Committee [05/Q2403/24] 
123 and Derby Research Ethics Committee 1 [11/H0405/2]. Symptomatic chondropathy 
124 samples were from patients fulfilling American College of Rheumatology classification 
125 criteria for OA24 at the time of TKR.
126 Macroscopic chondropathy score and osteophytes
127 Following tissue harvesting, articular surfaces of the medial tibial plateau were 
128 evaluated on the extent and severity of loss of surface integrity by a single assessor25.
129 Articular surface defects were graded 0 [normal, smooth unbroken surface], 1 [swelling 
130 and softening], 2 [superficial fibrillation], 3 [deep fibrillation] and 4 [subchondral bone 
131 exposure]. The proportion of articular surface area corresponding to each grade was 
132 used to calculate a macroscopic chondropathy score (0-100) by the following formula
133 Macroscopic chondropathy score (0-100) = (Grade 1 x 0.14) + (Grade 2 x 0.34) + 
134 (Grade 3 x 0.65) + Grade 425. Osteophytes were documented on direct visualization of 
135 PM samples as present or absent.
136 Radiographic OA severity score. 
137 Radiographic OA severity scores were derived using preoperative postero-anterior knee 
138 radiographs as previously described25. An atlas of line drawings of the knee joint was 
139 used to grade medial and lateral joint space narrowing and osteophytes26. The scores for 
140 tibiofemoral joint space narrowing (range 0–6) and osteophytes (range 0–12) were 
141 summed to provide a total radiographic OA severity score (range 0–18)25.
142 Sample processing
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143 Mid-coronal sections of the middle third of medial tibial plateaux (an important weight 
144 bearing area characteristically affected by OA) were fixed in neutral buffered formalin 
145 then decalcified in 10% ethylenediaminetetraacetic acid (EDTA) in 10 mM Tris buffer 
146 (pH 6.95, 4°C) prior to wax embedding. Synovial tissues were fixed in formalin and 
147 wax embedded without decalcification.
148 Histology and grading
149 Tibial plateaux sections (5 µm) were stained with haematoxylin and eosin, or Safranin-
150 O and fast green. OA articular cartilage changes were graded using the Mankin scoring 
151 system27 ; cartilage surface integrity (0 [normal] to 6 [complete disorganisation]), 
152 tidemark integrity (0 [intact] or 1 [crossed by vessels]), chondrocyte morphology (0 
153 [normal] to 3 [hypocellular]) and proteoglycan loss (0 [normal, no loss of Safranin-O 
154 stain] to 4 [complete loss of stain]). Subchondral bone marrow replacement by 
155 fibrovascular tissue was assessed as either present or absent. Subchondral osteosclerosis 
156 was histologically assessed using trabecular bone volume per total volume (BV/TV) and 
157 subchondral plate area (µm2/µm); which were quantified using computer-assisted 
158 image analysis (Zeiss Systems). Osteochondral channel densities were assessed for 
159 subchondral bone, calcified cartilage and non-calcified cartilage separately in each 
160 region. Channels passing through one region into another were counted as in the region 
161 occupied by the larger part of the channel. Synovial inflammation was assessed using 
162 synovitis histological score developed by Haywood et al28; (0 [no synovitis] to 3 [severe 
163 synovitis]).
164 Immunohistochemistry
165 Sections underwent antigen retrieval (10 mM citrate buffer, 90°C, 20 mins) and blocked 
166 with 5% bovine serum albumin (BSA) containing goat serum, followed by incubation 
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167 with rabbit monoclonal antibody to NGF (EP1320Y, Abcam, Cambridge, UK), and 
168 biotinylated goat anti-rabbit IgG secondary antibody (BA1000, Vector, Peterborough, 
169 UK). CD68 immunoreactivity was visualized after citrate buffer antigen retrieval 
170 (1mg/ml pepsin in 0.5M acetic acid, 37˚C, 2h), and incubations with mouse monoclonal 
171 anti-human CD68 (MA5-13324, Thermo Fisher, MA, USA), and biotinylated horse 
172 anti-mouse IgG secondary antibody (BA2001, Vector, Peterborough, UK). 
173 Visualisation of NGF and CD68 immunoreactivites used avidin-biotincomplex (ABC) 
174 peroxidise (Vector, Peterborough, UK) with nickel-enhanced diaminobenzidine (DAB) 
175 development29. Sections were counterstained with hematoxylin so that different regions 
176 are more apparent.
177 NGF expression was measured as proportion (%) of osteochondral channels in each 
178 case that displayed NGF-immunoreactive cells. Subchondral tissues within 400 
179 micrometers of the cement line in the osteochondral junction were classified as bone 
180 marrow or fibrovascular tissues and NGF-like immunoreactivity was graded in each 
181 subchondral tissue type as: 0, none; 1, focal/sparse distribution; and 2, high density, and 
182 in chondrocyte as: grades 0 (<5% of cells); 1 (5-20% of cells); and 2 (>20% of cells)20. 
183 CD68-immunoreactive macrophages were graded in subchondral tissues as: 0, none; 1, 
184 focal/sparse distribution; and 2, high density20.
185 Tartrate-Resistant Acid Phosphatase (TRAP) Staining
186 Differentiated osteoclasts were identified by TRAP staining, using a commercially 
187 available kit (#386A Sigma-Aldrich, 160 UK) following the manufacturer’s protocol. 
188 TRAP positive osteoclasts were counted within 400 µm of the cement line in the 
189 osteochondral junction and divided by the length of the subchondral bone to give an 
190 osteoclast density expressed as TRAP positive cells per mm22. One dark purplish or 
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191 reddish cell with at least 3 nuclei or more was counted as one osteoclast. 
192 Image analysis
193 All histological scoring and quantification was undertaken by a single observer (KA) 
194 who was blinded to diagnostic group, using a Zeiss Axioscop-50 microscope (Carl 
195 Zeiss, Welwyn Garden City, UK). 
196 Statistical analysis
197 Statistical analyses were performed with JMP, Version 10 (SAS Ins. Cary, NC). 
198 Comparisons used Mann-Whitney U or chi-square tests. Logistic regression was 
199 performed to adjust for age and synovitis scores and to calculate McFadden's pseudo-
200 R2. The R2 for each linear regression model was recorded for each of the individual 
201 histological measures (NGF alone, osteoclasts alone, or synovitis score alone) and also 
202 for the linear regression model where all measures were included together (NGF, 
203 osteoclasts and synovitis). Spearman’s rank correlation (r) assessed associations. 
204 P<0.05 indicated statistically significance.
205
206 Results
207 Patient details
208 Demographics and sample details of cases selected for this study and for source repository 
209 cases are shown in Table 1. The selected asymptomatic chondropathy group　had similar 
210 macroscopic chondropathy score and proportion of joint surface area displaying grade 4 
211 chondropathy by matching to the symptomatic chondropathy group. The asymptomatic 
212 chondropathy group however had more severe OA changes than did the total cases in the 
213 post mortem repository from which they were selected. The asymptomatic chondropathy 
214 group was older than the symptomatic chondropathy group. There were no cases using 
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215 medications for osteoporosis in either group.
216 Histological characteristics
217 Histological characteristics of the study groups are shown in Figure 1 and Table 2. 
218 Osteochondral channels containing inflammatory cells and blood vessels were observed 
219 in subchondral bone plate, calcified cartilage and non-calcified cartilage (Figure 1A, B). 
220 Mankin score, proportion of cases with fibrovascular marrow replacement, histological 
221 BV/TV, subchondral plate area and osteochondral channel densities were similar between 
222 symptomatic and asymptomatic chondropathy groups. However, synovitis scores were 
223 higher in the symptomatic than in the asymptomatic chondropathy group, and this 
224 difference remained significant after adjusting for age (aOR=2.75 [95% CI 1.35-6.20], 
225 p=0.01).
226  In samples of medial tibial plateau, NGF-immunoreactivity was detected in 
227 chondrocytes, subchondral mononuclear cells and in multinucleate osteoclast-like cells 
228 adherent to bone (Figure 1). NGF-immunoreactive cells were found in osteochondral 
229 channels, and in subchondral fibrovascular tissue and bone marrow (Figure 1). CD68-
230 immunoreactive macrophages were observed mainly in subchondral bone marrow and 
231 fibrovascular tissues (Figure 1). A higher proportion of osteochondral channels contained 
232 NGF-immunoreactive cells in the symptomatic than in the asymptomatic chondropathy 
233 group (Figure 2). This difference remained significant after adjusting for age and 
234 synovitis histological score (aOR=1.05 [95% CI 1.01-1.10], p=0.01). Scores for 
235 subchondral macrophage infiltration, and NGF-immunoreactivity in chondrocytes and 
236 subchondral fibrovascular tissue and bone marrow did not differ significantly between 
237 groups (Supplementary table 1). NGF-immunoreactive osteochondral channels were 
238 significantly associated with Mankin score and with its component scores for tidemark 
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239 integrity and cartilage surface integrity (Supplementary table 2).
240 TRAP-positive multinucleated osteoclasts were observed at the bone surface of 
241 subchondral bone (Figure 1). The density of osteoclasts in the subchondral bone in the 
242 symptomatic chondropathy group was significantly higher than in the asymptomatic 
243 chondropathy group (p=0.02) (Figure 2). This difference remained significant after 
244 adjusting for age and synovitis score (aOR=1.19 [95% CI 1.01-1.48], p=0.04). The 
245 percentage of NGF positive osteochondral channels was significantly correlated with the 
246 number of TRAP-positive osteoclasts (r=0.34, p=0.01). The association between NGF 
247 expression in osteochond al channels and symptomatic chondropathy remained 
248 significant after adjusting for osteoclasts density (aOR=1.05 [95% CI 1.01-1.09], p<0.01), 
249 but the significant association of osteoclast density with symptomatic chondropathy did 
250 not persist after adjusting for NGF expression in osteochondral channels (aOR =1.10 
251 [95% confidence interval 0.96-1.32], p=0.20). Synovitis scores were not significantly 
252 associated with either NGF-immunoreactive osteochondral channels (r=0.07, p=0.62), 
253 nor with subchondral TRAP-positive osteoclasts (r=0.11, p=0.44).
254 McFadden's pseudo-R2 values were 0.17, 0.13 and 0.05 for symptomatic versus 
255 asymptomatic group allocation for each of synovitis score, NGF expression in 
256 osteochondral channels and subchondral osteoclast density respectively, and 0.28 for the 
257 combination of all 3 histopathological features.
258 Discussion
259 We demonstrate components of subchondral pathology associated with symptomatic 
260 chondropathy in people undergoing knee arthroplasty for painful OA. We show that NGF 
261 expression in osteochondral channels and subchondral TRAP-positive osteoclast density 
262 each is associated with symptomatic chondropathy. We confirm previous findings10 that 
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263 symptomatic OA is associated with synovitis, and show that associations with 
264 subchondral pathology are not dependent on the severity of chondropathy or synovitis. 
265 OA can affect all tissues in the joint, and our data support a model of OA pain to which 
266 different joint tissue compartments make discrete contributions. 
267
268 Associations of symptomatic knee OA with osteochondral NGF
269 We found that the proportion of osteochondral channels positive for NGF-
270 immunoreactivity was a sensitive measure able to distinguish symptomatic and 
271 asymptomatic case groups, supporting a role for osteochondral NGF in the generation of 
272 OA pain. This association appears to be over and above any effect of synovitis or cartilage 
273 damage on joint pain. The number of osteochondral channels penetrating into non-
274 calcified cartilage is increased in OA20, but our findings suggest that this alone may not 
275 be sufficient to explain OA pain. We show that NGF-immunoreactivity in osteochondral 
276 channels was correlated with tidemark integrity, suggesting expression of sensitizing 
277 factors such as NGF as mediating effects of channels on OA pain. 
278 NGF may directly activate sensory neurons that express TrkA and modulate the 
279 expression of TrkA or p75 receptor30. Anti-NGF antibodies can reduce OA pain18, 19 
280 indicating the importance of NGF in pain generation, although their anatomical site of 
281 action remains uncertain. NGF has previously been localized to human synovium where 
282 it could be associated with OA pain10. OA chondrocytes may also express NGF10 although 
283 we were unable to demonstrate association of chondrocyte-derived NGF with 
284 symptomatic chondropathy. 
285  Increased NGF immunoreactive cells in osteochondral channels could contribute to OA 
286 pain, by increasing colocalized sensory nerve activity. NGF immunoreactive cells were 
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287 colocalized with sensory nerve fibers within osteochondral channels in human 
288 subchondral bone20. Indeed, most sensory neurons innervating the subchondral bone in 
289 rat knee joints were TrkA immunoreactive31, and TrkA expression in subchondral bone 
290 afferents was further increased during mono-iodoacetate-induced OA in rats9.
291
292 Associations of symptomatic knee OA with osteoclasts
293 Our results showed that osteoclast density in subchondral bone was associated with 
294 symptomatic knee OA and the differences remained significant after adjusting for age 
295 and synovitis histological score. Osteoclasts might increase pain either directly by 
296 changing the subchondral biochemical milieu, or by altering subchondral bone structure. 
297 Osteoclasts release protons that generate a local acidosis, potent activators of nociceptors 
298 that can increase pain signaling32. Our findings also indicate that osteoclasts are a source 
299 of NGF which could then sensitise primary afferents in the subchondral bone.
300 Classification of cases as symptomatic or asymptomatic was significantly predicted by 
301 NGF-immunoreactivity, but not by subchondral trabecular bone density. Our current 
302 results therefore extend findings from a previous study22 which reported a potential role 
303 of increased osteoclast density in subchondral bone in the generation of OA pain. High 
304 serum concentration of TRAP5b, an indicator of osteoclast number, was associated with 
305 subchondral osteoclast density, OA pain and worse pain prognosis22. We now show that 
306 association of osteoclast density with symptomatic OA is not explained by associations 
307 with chondropathy, synovitis, or age, suggesting a direct effect of osteoclasts on OA pain. 
308 Increased subchondral osteoclast number was also associated with pain behavior in rats33, 
309 34, and reducing the number of osteoclasts led to decreases in weight bearing pain34. 
310 Studies of osteoclast inhibitors such as bisphosphonates, denosumab and strontium 
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311 ranelate show reductions joint pain in people with knee OA35 36. The bisphosphonate 
312 zoledronic acid reduced knee pain and BML size in people with OA36, although a meta-
313 analysis of randomized controlled trials did not support analgesic effects of 
314 bisphosphonates in knee OA37. Our data suggest that OA knee pain has multiple sources, 
315 and targeting osteoclasts will only have clinically important benefit in those cases where 
316 osteoclast activity is the predominant driver of pain.
317
318 Associations between NGF and osteoclasts
319 We show associations between NGF and osteoclast densities in subchondral bone. 
320 Multinucleated osteoclasts were immunoreactive for NGF, and NGF expression in 
321 osteochondral channels was significantly correlated with the number of TRAP-positive 
322 osteoclasts. NGF expression in osteochondral channels was associated with symptomatic 
323 knee OA after adjusting for osteoclast density, but association of osteoclasts density with 
324 symptoms did not persist after adjusting for NGF. Our data support the view that NGF is 
325 a more important factor than osteoclast density in subchondral bone for the generation of 
326 OA pain.
327 Furthermore, NGF can act as an autocrine or paracrine factor regulating osteoclast 
328 activity and bone remodeling. NGF and TrkA are expressed by osteoclasts, and the 
329 addition of NGF to monocyte cultures induces the formation of TRAP-positive 
330 multinucleated cells38. An anti-NGF antibody reduced subchondral osteoclast numbers in 
331 a rat model of OA pain39. 
332
333 Contributions from discrete tissue compartments to knee symptoms
334 This is the first study evaluating associations between symptomatic OA and pathological 
Page 13 of 26
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review
335 changes in discrete tissue compartments of the human knee. Cases with more severe 
336 chondropathy are more likely to display synovitis and subchondral bone changes40. 
337 However, in the current study, subchondral changes were not significantly associated 
338 with synovitis grade and each compartment might contribute discretely to OA pain.
339 Our findings support a heterogeneous model of OA pain, resulting from multiple 
340 mechanisms in different peripheral tissues. The balance between pain mechanisms varies 
341 from person to person. Latent class analysis has indicated that synovitis is a key 
342 characteristic defining one subgroup of people with OA10. Our findings here suggest that 
343 subchondral pathology can define a subgroup of people with symptomatic chondropathy, 
344 only partially overlapping with cases whose OA pain is driven by synovitis.
345 MRI evidence of cartilage defects41, bone marrow lesions7 and synovitis12 can also 
346 discretely predict OA pain. We extend these findings to identify NGF-immunoreactive 
347 osteochondral channels and subchondral osteoclast densities as key pathological features 
348 which make discrete contributions to OA symptoms.
349 Our results showed that 28% of group allocation to symptomatic and asymptomtic 
350 chondropathy can be explained by the combination of synovitis score, NGF expression 
351 in osteochondral channels and subchondral osteoclast density. Synovitis score and NGF 
352 expression in osteochondral channels contributed to group allocation to similar extents 
353 (17% and 13%, respectively), and both may be important targets for future OA treatments.
354 Limitations
355 This study has several potential limitations. Some patients in our `asymptomatic’ 
356 chondropathy group might have experienced knee pain, but relatives may have been 
357 unaware of these symptoms. However, all patients undertaking TKR report severe knee 
358 pain, and it is highly likely that people who have not undergone surgery overall have less 
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359 pain than those who do. Symptomatic and asymptomatic chondropathy groups differed 
360 by age, although significant associations with subchondral pathology and synovitis 
361 persisted after adjusting our analyses for age. Samples were from the mid-coronal section 
362 of the medial tibial plateau, a key weight bearing area, but findings might differ for other 
363 joint regions such as femoral condyles. Symptomatic chondropathy cases had late-stage 
364 OA undergoing arthroplasty, and different pain mechanisms might be important in cases 
365 with less severe structural change. Osteoclast activity itself was not examined in this study. 
366 However, cell with at least 3 nuclei or more was counted as one osteoclast to estimate 
367 active osteoclasts, as resorption activity has been shown under some circumstances to 
368 correlate with the number of nuclei42. However, osteoclast numbers do not necessarily 
369 correlate with osteoclast activity, for example during bisphosponate treatment43. More 
370 direct measures, for example of biomarkers of collagen breakdown, might further clarify 
371 whether associations of symptoms with osteoclast number might reflect mediation by 
372 osteoclast activity. Our models did not explain all of the variance in classification to 
373 symptomatic and asymptomatic groups. Some variation might be attributable to case 
374 ascertainment (e.g. people in the asymptomatic group might have experienced some knee 
375 pain). Factors not explored here, such as other histopathologic changes, 
376 cytokines/molecules, psychological factors, biomechanical loading and obesity, are likely 
377 to also contribute to OA pain. BMLs are associated with knee OA pain. BMLs have been 
378 associated with cartilage surface integrity and subchondral bone marrow replacement by 
379 fibrovascular tissue8, both of which were similar between symptomatic and asymptomatic 
380 chondropathy groups in our study. However, MRI scans were not available for cases in 
381 our study, and further investigation is needed to clarify the association of BMLs with 
382 NGF expression in osteochondral channels and TRAP-positive osteoclast densities. Case 
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383 matching asymptomatic chondropathy cases from a total post-mortem sample group of 
384 782 knees enabled us to identify histopathological factors contributing to OA symptoms, 
385 but further research would need determine their importance relative to contributions from 
386 chondropathy itself.
387
388 Conclusions
389 We have identified histopathologic features of subchondral bone that are associated with 
390 symptomatic chondropathy. NGF expression in osteochondral channels was associated 
391 with symptomatic knee OA over and above any effects of chondropathy, synovitis and 
392 subchondral TRAP-positive osteoclast densities. Increased NGF expression appears as a 
393 key features associated with subchondral bone pain in knee OA, and could contribute to 
394 the previously observed association between osteoclasts and OA pain. Our data support 
395 a heterogeneous model of OA pain, with discrete contributions from different 
396 compartments in the joint. Different treatments could benefit pain from synovitis or from 
397 subchondral pathology, necessitating the development of biomarkers to help target 
398 treatments to those who will most benefit. Other treatments targeting molecular pathways 
399 that are shared between tissue compartments will have greater potential for efficacy in 
400 unselected OA populations. 
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552 Figure 1: Histopathologic features in subchondral bone
553 A; NGF-positive osteochondral channel (arrow head) in symptomatic chondropathy. B; 
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554 NGF-negative osteochondral channel (arrow) in asymptomatic chondropathy. NGF- 
555 immunoreactive cells (brown) were found in osteochondral channels (A), fibrovascular 
556 tissue (C) and bone marrow (D). Multinucleated osteoclasts were immunoreactive for 
557 NGF. (E). CD68-immunoreactive macrophages were mainly observed in bone marrow 
558 (F) and fibrovascular tissue (G). TRAP staining showed multinucleated osteoclasts 
559 (purple) (H). Scale bars = 50 μm
560
561 Figure 2: Immunoreactivity for NGF and TRAP-positive osteoclasts in the 
562 subchondral bone from symptomatic and asymptomatic chondropathy cases
563 Scatterplots illustrate the differences between symptomatic and asymptomatic 
564 chondropathy. Lines represent medians and IQR. *p < 0.01, and #p = 0.02 versus 
565 asymptomatic chondropathy.
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Symptomatic 
chondropathy
(n = 31 knees)
Asymptomatic 
chondropathy
(n = 31 knees)
Post-mortem 
repository
(n = 782 knees)
Macroscopic chondropathy score (0-100) 74 (56,80) 76 (56, 81) ## 33 (24, 51)
Joint surface area with grade 4 chondropathy (%) 30 (0, 48) * 30 (0, 50) ## 0 (0, 0)
Gender, Male (%) 51.6 61.3 54.5
Age (year) 67 (55, 73) * 74 (66, 84) # 69 (60, 80)
Total radiographic OA severity score (0-18) 13 (10.5, 13.5) NA NA
    Tibiofemoral JSN score (0-6) 5 (5, 5.8) NA NA
    Medial tibiofemoral JSN score (0-3) 3 (3, 3) NA NA
    Osteophyte score (0-12) 8 (5.5, 8) NA NA
    Medial tibial osteophyte score (0-3) 2 (2, 2) NA NA
MFC osteophytes (Yes/No) NA 16/14 (53.3%) ## 113/738 (15.3%)
LFC osteophytes (Yes/No) NA 18/11 (62.1%) ## 111/738 (15.0%)
MT osteophytes (Yes/No) NA 15/15 (50.0%) ## 87/738 (11.7%)
LT osteophytes (Yes/No) NA 13/17 (43.3%) ## 82/738 (11.1%)
Patellar osteophytes (Yes/No) NA 10/20 (50.0%) ## 41/358 (11.4%)
Table 1: Patient and sample details
Data displayed as median (IQR). Total radiographic OA severity score is a summation 
of tibiofemoral joint space narrowing (JSN) and osteophyte scores. Tibiofemoral JSN 
score is a summation of medial and lateral tibiofemoral JSN scores. Osteophyte score is 
a summation of medial and lateral tibial and femoral osteophyte scores. *p<0.01 versus 
asymptomatic chondropathy, #p=0.03, and ##p<0.01 versus the post-mortem repository. 
JSN; joint space narrowing, MFC; medial femoral condyle, LFC; lateral femoral 
condyle, MT; medial tibial plateau, LT; lateral tibial plateau, NA = Not available.
Symptomatic   
chondropathy
(n = 31 knees)
Asymptomatic 
chondropathy
(n = 31 knees)
P
Total Mankin score (0-14) 9 (7, 11) 8 (7, 11) 0.70
      Cartilage surface integrity (0-6) 4 (3, 6) 4 (3, 6) 0.98
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    Chondrocyte appearance (0-3) 2 (2, 3) 2 (2, 2) 0.45
    Tidemark integrity (0-1) 1 (0, 1) 0 (0, 1) 0.13
    Proteoglycan loss (0-4) 2 (2, 3) 2 (2, 3) 0.87
Subchondral bone marrow replacement 
(Yes/No)
11/20 (35%) 14/17 (45%) 0.44
Histological BV/TV 50.0 (42.0, 61.3) 57.3 (39.0, 63.0) 0.95
Subchondral plate area (µm2/µm) 608.3 (460.0, 810.6) 651.5 (431.7, 1050.0) 0.43
Total osteochondral channel density 
(/mm)
5.4 (3.7, 6.4) 4.9 (3.5, 7.4) 0.93
    Subchodral bone (/mm) 4.8 (3.3, 6.1) 4.7 (3.4, 7.2) 0.93
    Calcified cartilage (/mm) 0.24 (0.09, 57) 0.25(0, 0.46) 0.51
    Non-calcified cartilage (/mm) 0 (0, 0) 0 (0, 0)   0.89
  Synovitis histological score (0-3) 3 (2.75, 3) 1 (1, 2.5) <0.01
 Table 2: Osteochondral histology and synovitis scores
Data displayed as median (IQR). Total Mankin score is a summation of cartilage surface 
integrity, chondrocyte appearance, tidemark integrity, and proteoglycan loss. BV/TV is 
trabecular bone volume per total volume. Total osteochondral channel density is a 
summation of osteochondral channel densities in subchondral bone, calcified cartilage 
and non-calcified cartilage. 
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Figure 1: Histopathologic features in subchondral bone 
A; NGF-positive osteochondral channel (arrow head) in symptomatic chondropathy. B; NGF-negative 
osteochondral channel (arrow) in asymptomatic chondropathy. NGF- immunoreactive cells (brown) were 
found in osteochondral channels (A), fibrovascular tissue (C) and bone marrow (D). Multinucleated 
osteoclasts were immunoreactive for NGF. (E). CD68-immunoreactive macrophages were mainly observed in 
bone marrow (F) and fibrovascular tissue (G). TRAP staining showed multinucleated osteoclasts (purple) 
(H). Scale bars = 50 μm 
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Figure 2: Immunoreactivity for NGF and TRAP-positive osteoclasts in the subchondral bone from 
symptomatic and asymptomatic chondropathy cases 
Scatterplots illustrate the differences between symptomatic and asymptomatic chondropathy. Lines 
represent medians and IQR. *p < 0.01, and #p = 0.02 versus asymptomatic chondropathy. 
170x70mm (300 x 300 DPI) 
Page 25 of 26
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review
Symptomatic 
chondropathy
(n = 31 knees)
Asymptomatic 
chondropathy
(n = 31 knees)
P
NGF expression in fibrovascular tissue (0-2) 1 (1, 2) 2 (1, 2) 0.63
NGF expression in bone marrow (0-2) 1 (0, 1) 1 (0.75, 2) 0.11
NGF expression in chondrocyte (0-2) 1 (1, 2) 1 (1,2) 0.70
CD68-immunoreactive macrophage in 
fibrovascular tissue (0-2)
1 (1, 2) 2 (0.5, 2) 0.53
CD68-immunoreactive macrophage in bone 
marrow (0-2)
1 (1, 1) 1 (0, 2) 0.67
Supplementary table 1: Immunoreactivity for NGF and CD68 (macrophages) in the subchondral 
bone from symptomatic and asymptomatic chondropathy cases
Data displayed as median (IQR).
NGF expression Mankin score
Osteochon
dral 
channels
Fibrovascu
lar tissue
Bone 
marro
w
Chondro
cytes
Total  
Mankin 
score
Cartilage 
surface
integrity
Chondrocyte 
appearance
Tidemark 
integrity
Proteogl
ycan 
loss
Osteochondral 
channels
1 0.38 0.12 0.18 0.32* 0.26* 0.22 0.36** 0.14
Fibrovascular 
tissue
- 1 0.30 0.49* 0.46* 0.21 0.03 0.23 0.52*
Bone marrow - - 1 0.17 0.29* 0.25 0.17 0.07 0.23N
G
F 
ex
pr
es
si
on
Chondrocytes - - - 1 0.24 0.25 0.04 0.17 0.24
Supplementary table 2: Correlation of NGF expression in subchondral bone tissue and chondrocytes 
with Mankin score
Data displayed as Spearman’s r. *p < 0.05, ** p < 0.01
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